Genprex Appoints John N. Bonfiglio, PhD, to Board of Directors

Experienced Biotech Executive Brings More Than 30 Years of
Pharmaceutical and Biotechnology Experience to Genprex

AUSTIN, Texas & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Genprex,
Inc.
(NASDAQ: GNPX)
a clinical-stage gene therapy company developing a new approach to
treating cancer based upon a novel proprietary technology platform,
announced today the appointment of John N. Bonfiglio, PhD, to the
company’s Board of Directors. In recent years, Dr. Bonfiglio served as
President and CEO of Oragenics, Inc. and most recently as President and
COO of TapImmune, Inc., where he helped lay the groundwork for a
successful merger with Marker Therapeutics, Inc. in October 2018 by
up-listing TapImmune to Nasdaq and starting a robust clinical program in
breast and ovarian cancers. John’s more than 30 years of experience in
the pharmaceutical and biotechnology industries will enable the Genprex
Board and management team to draw on his expertise to help guide Genprex
as it continues to grow.


“I am honored and excited to join Genprex’s Board of Directors,” Dr.
Bonfiglio said. “I see tremendous potential for Genprex. In my opinion,
Genprex’s clinical and pre-clinical research show that its lead drug
candidate, Oncoprex™ immunogene therapy, can potentially work
synergistically in combination with targeted therapies and
immunotherapies to treat cancer patients outside of the population
normally targeted by these cancer therapies. Clinical exploration of
these areas could lead to market expansion and to new patient
populations with unmet medical needs. The market potential for these new
combination therapies is very attractive.”

Dr. Bonfiglio began his career as a scientist with Allergan, Inc. before
moving into project and business development. Over the course of his
career he has held several executive leadership positions including
President and CEO at Peregrine Pharmaceuticals, Inc., Executive Vice
President and COO of Cypress Bioscience, Inc., President and CEO of The
Immune Response Corporation and the President and CEO of Argos
Therapeutics, Inc., among others. In those positions, he has succeeded
in raising capital, lowering burn rates, setting corporate strategies,
controlling corporate spending and managing clinical trials. Throughout
his career he has helped raise more than $150 million in capital while
helping companies relist and up-list with national securities exchanges.
Recently, he joined the Board of Directors of GT Biopharma, Inc., adding
to his significant experience in the immuno-oncology field.

“We are excited that Dr. Bonfiglio has accepted our invitation to join
our Board of Directors,” said Rodney Varner, Genprex’s Chief Executive
Officer and Chairman. “His experience and expertise are impressive. His
background with other biotechnology companies will provide us with
extensive knowledge and resources. We believe that Dr. Bonfiglio will
make a great contribution to our future success.”

Dr. Bonfiglio’s appointment to the Board is the latest high-profile
addition to Genprex as the company continues to grow. In October 2018,
Genprex appointed Jan Stephens, RN, as the company’s Vice President of
Clinical Operations.

About Genprex, Inc.

Genprex, Inc. is a clinical stage gene therapy company developing
potentially life-changing technologies for cancer patients, based upon a
unique proprietary technology platform, including Genprex’s initial
product candidate, Oncoprex™ immunogene therapy for non-small cell lung
cancer (NSCLC). Genprex’s platform technologies are designed to
administer cancer fighting genes by encapsulating them into nanoscale
hollow spheres called nanovesicles, which are then administered
intravenously and taken up by tumor cells where they express proteins
that are missing or found in low quantities. Oncoprex has a multimodal
mechanism of action whereby it interrupts cell signaling pathways that
cause replication and proliferation of cancer cells, re-establishes
pathways for apoptosis, or programmed cell death, in cancer cells, and
modulates the immune response against cancer cells. Oncoprex has also
been shown to block mechanisms that create drug resistance. Visit the
company’s web site at www.genprex.com
or follow Genprex on Twitter at twitter.com/genprex,
Facebook at facebook.com/genprexinc
and LinkedIn at linkedin.com/company/genprex.

Forward-Looking Statements

Statements contained in this press release regarding matters that are
not historical facts are “forward-looking statements” within the meaning
of the Private Securities Litigation Reform Act of 1995. Because such
statements are subject to risks and uncertainties, actual results may
differ materially from those expressed or implied by such
forward-looking statements. Such statements include, but are not limited
to, statements regarding the effects of Oncoprex™, and statements
regarding the synergies obtained by combining Oncoprex with targeted
therapies and immunotherapies. Risks that contribute to the uncertain
nature of the forward-looking statements include the extent of
Oncoprex’s effect on cancer, as well as the timing and success of our
clinical trials and planned clinical trials of Oncoprex and our other
potential product candidates and the timing and success of obtaining FDA
approval of Oncoprex and our other potential product candidates. These
and other risks and uncertainties are described more fully under the
caption “Risk Factors” and elsewhere in our filings and reports with the
United States Securities and Exchange Commission. All forward-looking
statements contained in this press release speak only as of the date on
which they were made. We undertake no obligation to update such
statements to reflect events that occur or circumstances that exist
after the date on which they were made.

Contacts

Genprex, Inc.
(877) 774-GNPX (4679)

Investor Relations
GNPX investor relations
(877)
774-GNPX (4679) ext. #2
[email protected]

Media Contact
Genprex Media Relations
(877) 774-GNPX
(4679) ext. #3
[email protected]

error: Content is protected !!